Advertisement

Topics

H. Lundbeck A/S: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease

12:04 EDT 22 Sep 2016 | FinanzNachrichten

-- In the first study, idalopirdine did not meet the primary endpoint -- Idalopirdine was safe and well tolerated -- The remaining two phase III studies are expected to report data in the first qua...

Original Article: H. Lundbeck A/S: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease

NEXT ARTICLE

More From BioPortfolio on "H. Lundbeck A/S: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...